WO2008151633A3 - Vectors for vaccines against lentivirus infections - Google Patents
Vectors for vaccines against lentivirus infections Download PDFInfo
- Publication number
- WO2008151633A3 WO2008151633A3 PCT/DK2008/000217 DK2008000217W WO2008151633A3 WO 2008151633 A3 WO2008151633 A3 WO 2008151633A3 DK 2008000217 W DK2008000217 W DK 2008000217W WO 2008151633 A3 WO2008151633 A3 WO 2008151633A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- lentiviral
- hiv
- envelope
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a lentiviral envelope polypeptide or a nucleic acid sequence encoding a lentiviral envelope polypeptide, which are capable of inducing an immunogenic response against lentiviral infection, such as HIV infection. Examples of envelopes are HIV-1, HIV-2 or SIV envelope proteins or variants thereof. A specific such envelope variant is devoid of its C-terminal domain. The lentiviral envelope polypeptide or nucleic acid encoding said polypeptide is provided in vectors, methods, proviruses, retroviral particles, uses, compositions, vaccines, vaccine compositions and kits. Moreover, the lentiviral envelope polypeptide or nucleic acid encoding said polypeptide may be provided in combination with other compounds, such as selective marker genes, adjuvants, and immunomodulating agents. The invention is applicable for generation of retroviral particles for specific targeting of host cells. The retroviral particles may be used for integration of trangenes in host cells and induction of an immunogenic response, for example against HIV-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200700861 | 2007-06-15 | ||
DKPA200700861 | 2007-06-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008151633A2 WO2008151633A2 (en) | 2008-12-18 |
WO2008151633A3 true WO2008151633A3 (en) | 2009-04-23 |
Family
ID=39816797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2008/000217 WO2008151633A2 (en) | 2007-06-15 | 2008-06-13 | Vectors for vaccines against lentivirus infections |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008151633A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018240A1 (en) | 1998-10-01 | 2000-04-06 | University Of Southern California | Gene delivery system and methods of use |
US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
WO2010045002A2 (en) | 2008-09-26 | 2010-04-22 | Tocagen Inc. | Gene therapy vectors and cytosine deaminases |
US9669049B2 (en) | 2010-10-31 | 2017-06-06 | Tocagen Inc. | Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders |
WO2014066700A1 (en) | 2012-10-25 | 2014-05-01 | Tocagen Inc. | Retroviral vector with mini-promoter cassette |
US9642921B2 (en) | 2012-12-20 | 2017-05-09 | Tocagen Inc. | Cancer combination therapy and recombinant vectors |
CN103520717B (en) * | 2013-09-02 | 2015-11-18 | 中山大学 | Alanine is as the application of vaccine adjuvant |
JP2018526007A (en) | 2015-09-04 | 2018-09-13 | トカジェン インコーポレーテッド | Recombinant vector containing 2A peptide |
CN111263816A (en) * | 2017-10-23 | 2020-06-09 | 吴云涛 | Lentiviral-dependent vaccine particles reduce viral rebound and viral stocks in vivo |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999020742A2 (en) * | 1997-10-20 | 1999-04-29 | Universita' Degli Studi Di Padova | A packaging cell line producing siv-pseudotyped mlv |
-
2008
- 2008-06-13 WO PCT/DK2008/000217 patent/WO2008151633A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999020742A2 (en) * | 1997-10-20 | 1999-04-29 | Universita' Degli Studi Di Padova | A packaging cell line producing siv-pseudotyped mlv |
Non-Patent Citations (11)
Title |
---|
BABIUK L A ET AL: "Induction of immune responses by DNA vaccines in large animals", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 7-8, 30 January 2003 (2003-01-30), pages 649 - 658, XP004401599, ISSN: 0264-410X * |
CAVER T E ET AL: "A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 11-12, 1 March 1999 (1999-03-01), pages 1567 - 1572, XP004158286, ISSN: 0264-410X * |
DATABASE EMBL [online] 21 March 2001 (2001-03-21), "HIV-1 from USA from USA envelope glycoprotein (env) gene, partial cds.", XP002517507, retrieved from EBI accession no. EMBL:AF321147 Database accession no. AF321147 * |
DATABASE Geneseq [online] 15 July 2004 (2004-07-15), "HIV gene for anti-HIV vaccine.", XP002517506, retrieved from EBI accession no. GSN:ADN36424 Database accession no. ADN36424 * |
DEVITT ET AL: "Incorporation of chimeric HIV-SIV-Env and modified HIV-Env proteins into HIV pseudovirions", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 361, no. 2, 17 April 2007 (2007-04-17), pages 465 - 471, XP022029916, ISSN: 0042-6822 * |
HAMMARSKJOELD MARIE-LOUISE ET AL: "Human immunodeficiency virus env expression becomes rev-independent if the env region is not defined as an intron", JOURNAL OF VIROLOGY, vol. 68, no. 2, 1994, pages 951 - 958, XP002500726, ISSN: 0022-538X * |
JIAN-MING X ET AL: "Immunogenic potential of rgp120 from African HIV-1 subtype A", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 14, no. 10, 1 July 1996 (1996-07-01), pages 993 - 1000, XP004057631, ISSN: 0264-410X * |
MAMMANO F M ET AL: "TRUNCATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENVELOPE GLYCOPROTEIN ALLOWS EFFICIENT PSEUDOTYPING OF MOLONEY MURINE LEUKEMIA VIRUS PARTICLES AND GENE TRANSFER INTO CD4+ CELLS", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 4, 1 April 1997 (1997-04-01), pages 3341 - 3345, XP002074198, ISSN: 0022-538X * |
SCHNIERLE BARBARA S ET AL: "Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 94, no. 16, 1997, pages 8640 - 8645, XP002517504, ISSN: 0027-8424 * |
WANG ET AL: "Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 24, no. 21, 22 May 2006 (2006-05-22), pages 4531 - 4540, XP005463444, ISSN: 0264-410X * |
YAN JIAN ET AL: "Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY FEB 2007, vol. 15, no. 2, February 2007 (2007-02-01), pages 411 - 421, XP002517505, ISSN: 1525-0016 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008151633A2 (en) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008151633A3 (en) | Vectors for vaccines against lentivirus infections | |
ATE527281T1 (en) | VACCINES AGAINST AIDS COMPRISING CMV/R NUCLEIC ACID CONSTRUCTS | |
NZ602504A (en) | Antiviral vaccines with improved cellular immunogenicity | |
MX2011011186A (en) | A tuberculosis tb vaccine to prevent reactivation. | |
WO2010022740A3 (en) | Hiv-1 envelope polypeptides for hiv vaccine | |
MY145614A (en) | Vaccine | |
WO2007149491A3 (en) | Soluble stabilized trimeric hiv env proteins and uses thereof | |
WO2008063331A3 (en) | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof | |
BRPI0813194A2 (en) | combination of compounds, lentiviral vector particles, lentiviral vectors, plasmid vector composition, plasmid vector, chimeric hiv-1 derived antigen, vsv-g envelope protein, nucleic acid molecules, immunogenic composition, and use of a lentiviral vector | |
WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
ATE494906T1 (en) | CELL-DERIVED VIRAL VACCINES WITH LOW AMOUNTS OF RESIDUAL CELL DNA | |
EA200701128A1 (en) | Recombinant strains of BCG, possessing enhanced ability to release from endosomes. | |
WO2010019262A3 (en) | Polyvalent vaccine | |
WO2011106607A3 (en) | Subunit vaccines for herpes viruses and methods of use | |
WO2005111079A3 (en) | Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41 | |
EA201892233A1 (en) | COMPOSITIONS AND METHODS ASSOCIATED WITH HIV-1 IMMUNOGENES | |
AU2021238777A8 (en) | Modified mRNAs for vaccine development | |
SG178909A1 (en) | Generation of a broad t-cell response in humans against hiv | |
WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
BR0206823A (en) | Chimeric gene, chimeric protein, recombinant virus, vaccine composition, use of a vaccine composition, therapeutic or preventive combination, and plasmid | |
WO2010041241A3 (en) | Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding | |
WO2011038473A8 (en) | Method, kit, plasmid and composition for inducing an immune response to dengue virus, on the basis of dna and chimeric virus vaccines | |
TW201008576A (en) | New fusion proteins and their use for the preparation of vaccines against hepatitis C | |
FR2829498B1 (en) | IGF-1 AS A FELINE VACCINE ADJUVANT, ESPECIALLY AGAINST FELINE RETROVIRUSES | |
WO2006091455A3 (en) | Molecular scaffolds for hiv-1 immunogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08758226 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08758226 Country of ref document: EP Kind code of ref document: A2 |